Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23235276 | 0.83 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2MAPTGAAKDM4E | |
| SCHEMBL18876516 | 0.81 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL31494990 | 0.81 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2LMNAMAPTGAA | |
| SCHEMBL4934676 | 0.81 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2LMNAMAPTGAA | |
| SCHEMBL15330735 | 0.81 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2MAPTHTR2C | |
| Hydrochloric Acid SCHEMBL29952847 | 0.80 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2LMNAMAPTGAA | |
| SCHEMBL14922241 | 0.79 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2LMNAMAPTADRB1 | |
| SCHEMBL2649639 | 0.79 | ADRB1 (0.44) | ALDH1A1LMNAADRB1CHRM2CHRM4 | |
| SCHEMBL6223415 | 0.79 | ALDH3A1 (0.53) | ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL26181596 | 0.78 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2LMNAMAPTADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034152-A1 | METHOD FOR PREPARING TRIAZOLOPYRIMIDINONE DERIVATIVE | ST PHARM CO., LTD. (KR) | 2025-01-30 | — | — | US | disclosed |
| EP-4442687-A1 | METHOD FOR PREPARING TRIAZOLOPYRIMIDINONE DERIVATIVE | ST Pharm Co., Ltd. (KR) | 2024-10-09 | — | — | EP | disclosed |
| CN-118284609-A | Process for preparing triazolopyrimidinone derivatives | ST制药株式会社 | 2024-07-02 | — | — | CN | disclosed |
| WO-2023101048-A1 | METHOD FOR PREPARING TRIAZOLOPYRIMIDINONE DERIVATIVE | 에스티팜 주식회사 | 2023-06-08 | — | — | WO | disclosed |
| WO-2023101048-A1 | METHOD FOR PREPARING TRIAZOLOPYRIMIDINONE DERIVATIVE | 에스티팜 주식회사 | 2023-06-08 | — | — | WO | disclosed |
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | disclosed |
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | disclosed |
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | disclosed |
| EP-1858869-A1 | ACYLATED PIPERIDINES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006094842-A1 | ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006094842-A1 | ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | SLC1A1, SLC6A7, SLC1A2 | ALDH1A1 1291/4885SMN1; SMN2 3393/4885LMNA 4248/4885 |
| US-20250034152-A1 | METHOD FOR PREPARING TRIAZOLOPYRIMIDINONE DERIVATIVE | TNKS1BP1, TNKS, TPI1 | ALDH1A1 1918/4885SMN1; SMN2 3483/4885LMNA 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.